Trends for Incidence of Hospitalization and Death Due to GI Complications in the United States From 2001 to 2009

Laine, Loren; Yang, Huiying; Chang, Shy Shin; Datto, Catherine

doi:10.1038/ajg.2012.168

Cited by 318 publications

(257 citation statements)

References 8 publications

Supporting

Mentioning

233

Contrasting

Unclassified

Order By: Relevance

“…Based on small studies conducted at tertiary referral centers, upper gastrointestinal hemorrhage mortality was reported until recently to be constant for the past five decades. With the availability of large and powerful national databases in the USA, more accurate estimates became possible and confirmed what has long been suspected: that both variceal and non-variceal gastrointestinal hemorrhage mortality has actually been decreasing over the last several decades [1,3,4]. In this issue of Digestive Diseases and Sciences, Wuerth et al report their results of a longitudinal retrospective database analysis that used the Nationwide Inpatient Sample (NIS) for calendar years 2002-2012 [5].…”

mentioning

confidence: 93%

See 1 more Smart Citation

Epidemiology of Upper Gastrointestinal Hemorrhage in the USA: Is the Bleeding Slowing Down?

Abougergi

2018

Dig Dis Sci

View full text Add to dashboard Cite

mentioning

confidence: 93%

“…Multiple studies have attempted to describe the impact of those changes on the epidemiology and treatment outcomes of patients with upper gastrointestinal hemorrhage [1,3,4]. Based on small studies conducted at tertiary referral centers, upper gastrointestinal hemorrhage mortality was reported until recently to be constant for the past five decades.…”

mentioning

confidence: 99%

Epidemiology of Upper Gastrointestinal Hemorrhage in the USA: Is the Bleeding Slowing Down?

Abougergi

2018

Dig Dis Sci

View full text Add to dashboard Cite

“…Moreover, the side effects associated with NSAID use can impose significant financial burden. 4,126,127 In the United States, the estimated direct medical cost associated with hospital care of UGIB is more than $2.5 billion annually. 126 Despite the availability of inexpensive NSAID treatment options, this potential financial benefit may be offset by the cost associated with preventing or treating NSAID-related complications.…”

Section: Balancing the Risks: Use Of Nsaids In Patients With Gastroinmentioning

confidence: 99%

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Atchison¹,

Herndon²,

Rusie³

2013

JMCP

View full text Add to dashboard Cite

and completed residency training in physical medicine and rehabilitation at The Ohio State University. Dr. Atchison has been in practice at academic medical centers for more than 20 years, serving on the faculty at the University of Kentucky and University of Florida before his appointment at Northwestern University. A recognized teacher and researcher in the field of pain management and rehabilitation, he has presented courses, lectures, and workshops nationally and internationally on pharmacological and nonpharmacological therapies, care of spinal injuries, and spinal manipulation. Dr. Atchison has led and participated in many research projects, including several funded by the National Institutes of Health. He has authored numerous research papers and book chapters, and he serves as a peer reviewer for the Archives of Physical Medicine and Rehabilitation. He has been a member of the editorial boards of the Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. S14 Multitarget Drugs S15 Conclusions S15 References Target AudiencesThis CME/CE activity is designed to meet the educational needs of pharmacists, physicians, nurse practitioners, and nurses. Learning Objectives• Assess patient-specific risk factors in selecting NSAIDs for mild-to-moderate musculoskeletal pain • Incorporate risk/benefit analysis in decision making about NSAID use • Use evidence-based guidelines for selecting NSAID therapy and applying strategies to prevent complications • Evaluate the efficacy, safety, and pharmacological profile of new and emerging NSAID formulations Funding This supplement was funded by an independent educational grant to PRIME Education, Inc. (PRIME) from Iroko Pharmaceuticals, LLC. Accreditation StatementsIn support of improving patient care, PRIME Education, Inc. (PRIME) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing educat...

show abstract

“…LGIB usually causes hematochezia, melena, or blood streaking of the stool [7] [8] [9]. Patients usually present with painless hematochezia and a decrease in hematocrit value, but without orthostasis [3] [8].…”

Section: Introductionmentioning

confidence: 99%

“…LGIB represents a significant cause of morbidity and mortality, It has an annual incidence of hospitalization of approximately 36/100,000 population and the rate of hospitalization is even higher in the elderly with an overall mortality rate ranging from 2% to 4% [7] [8].…”

Section: Introductionmentioning

confidence: 99%

Etiological Profile of Patients Presenting with Lower Gastrointestinal Bleeding in Ibb Governorate-Yemen

Kassim¹,

Al-Qubaty²,

Alathwary³

et al. 2018

OALib

View full text Add to dashboard Cite

Objectives: To investigate the causes of lower gastrointestinal bleeding (LGIB) in Yemeni patients and to compare our results with the results of other studies. Design: Prospective study of patients with overt LGIB during the period from April 2017 to March 2018. Setting: Specialized center of gastrointestinal and liver diseases in Ibb city, Yemen. Subjects & Method: Consecutive patients who presented or referred to our center with LGIB to whom lower GI endoscopy was performed. Results: During the study period, we had 122 patients with LGIB, 72 were males and 50 were females, with male:female ratio of 1.4:1 The age ranged between 5 and 82 years and the mean age was 45 ± 17.99 years. The clinical presentations of our patients included hematochezia in 72.1%, abdominal pain in 51.7%, diarrhea in 43.3%, pallor, and anemia in 40.2%, weight loss in 39.3%, constipation in 16.4%, bloody diarrhea in 16.4%, and melena in 5.7%. The most common colonoscopic findings were hemorrhoids in 36.7% followed by colon cancer in 19.7% and nonspecific colitis in 15.6%. Conclusion: Hemorrhoids and colon cancer were the most common causes of lower GI bleeding in our patients.

show abstract

Trends for Incidence of Hospitalization and Death Due to GI Complications in the United States From 2001 to 2009

Cited by 318 publications

References 8 publications

Epidemiology of Upper Gastrointestinal Hemorrhage in the USA: Is the Bleeding Slowing Down?

Epidemiology of Upper Gastrointestinal Hemorrhage in the USA: Is the Bleeding Slowing Down?

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Etiological Profile of Patients Presenting with Lower Gastrointestinal Bleeding in Ibb Governorate-Yemen

Contact Info

Product

Resources

About